Plasmodium falciparum: Higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda

Tropical Medicine and International Health

Volumn 10, Issue 6, 2005, Pages 537-543

  Sendagire, Hakim ^a   Kyabayinze, Daniel ^a   Swedberg, Göte ^b   Kironde, Fred ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dihydrofolate reductase; Dihydropteroate synthase; Molecular markers; Plasmodium falciparum; Pyrimethamine; Sulphadoxine

Indexed keywords

BIOCHEMICAL MARKER; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; PYRIMETHAMINE; SULFADOXINE;

DISEASE CONTROL; DRUG PRESCRIBING; MALARIA; MOLECULAR ANALYSIS;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CLINICAL FEATURE; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENE MUTATION; HEALTH CARE POLICY; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MONOTHERAPY; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; PREVALENCE; TREATMENT OUTCOME; UGANDA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; CODON; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENETIC MARKERS; HAPLOTYPES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PYRIMETHAMINE; SEQUENCE ANALYSIS, DNA; SULFADOXINE; TREATMENT OUTCOME; UGANDA;

AFRICA; EAST AFRICA; EASTERN HEMISPHERE; SUB-SAHARAN AFRICA; UGANDA; WORLD;

PLASMODIUM FALCIPARUM;

EID: 20444415657     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2005.01414.x     Document Type: Article

References (26)

1. Anonymous (1991) Uganda faces health crisis. Africa Analysis June 14, 14.
2. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R & Campbell CC (1993) Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. Journal of Infectious Diseases 167, 932-937.
3. Bloland PB, Ettling M & Meek S (2000) Combination therapy for malaria in Africa: hype or hope? Bulletin of the World Health Organization 78, 1378-1388.
4. Bousema JT, Gouagna LC, Meutstege AM et al. (2003) Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Tropical Medicine and International Health 8, 427-430.
5. Bwijo B, Kaneko A, Takechi M et al. (2003) High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Tropica 85, 363-373.
6. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ & Dorsey G (2003) Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study, comparison of results based on genotyping of msp-1, msp-2, and glurp. American Journal of Tropical Medicine and Hygiene 68, 133-139.
7. Domarle O, Migot-Nabias F, Mvoukani JL et al. (1999) Factors influencing resistance to reinfection with Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 61, 926-931.
8. Dorsey G, Njama D, Kamya MR et al. (2002) Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360, 2031-2038.
9. Dorsey G, Vlahos J, Kamya MR, Staedke SG & Rosenthal PJ (2003) Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with arcesunate or amodiaquine for the sequential treatment of malaria. Journal of Infectious Diseases 188, 1231-1238.
10. Duraisingh MT, Curtis J & Warhurst DC (1998) Plasmodium falciparum: detection of polymorphisms in dihydrofolate reductase and dihydropteroate synthetase by PCR and restriction digestion. Experimental Parasitology 89, 1-8.
11. Iyer JK, Milhous WK, Cortese JF, Kublin JG & Plowe CV (2001) Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358, 1066-1067.
12. Jelinek T, Kilian AH, Curtis J et al. (1999a) Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children. American Journal of Tropical Medicine and Hygiene 61, 125-130.
13. Jelinek T, Kilian AH, Kabagambe G & von Sonnenburg F (1999b) Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes. American Journal of Tropical Medicine and Hygiene 61, 463-466.
14. Kamya MR, Dorsey G, Gasasira A et al. (2001) The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 50-55.
15. Kamya MR, Bakyaita NN, Talisuna AO, Were WM & Staedke SG (2002) Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Tropical Medicine and International Health 7, 1031-1041.
16. Kublin JG, Dzinjalamala FK, Kamwendo DD et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Journal of Infectious Diseases 185, 380-388.
17. Masimirembwa CM, Phuong-dung N, Phuc BQ et al. (1999) Molecular epidemiology of Plasmodium falciparum antifolate resistance in Vietnam: genotyping for resistance variants of dihydropteroate synthase and dihydrofolate reductase. International Journal of Antimicrobial Agents 12, 203-211.
18. Ndyomugyenyi R & Magnussen P (1997) In vivo sensitivity of Plasmodium falciparum to chloroquine and Sulfadoxine-pyrimethamine in school children in Hoima district, Western Uganda. Acta Tropica 66, 137-143.
19. Ogutu BR, Smoak BL, Nduati RW, Mbori-Ngacha DA, Mwathe F & Shanks GD (2000) The efficacy of pyrimethamine-sulfadoxine (Fansidar) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children. Transactions of the Royal Society of Tropical Medicine and Hygiene 94, 83-84.
20. Plowe CV, Djimde A, Bouare M, Doumbo O & Wellems TE (1995) Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. American Journal of Tropical Medicine and Hygiene 52, 565-568.
21. Roper C, Pearce R, Bredenkamp B et al. (2003) Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361, 1174-1181.
22. Shulman CE, Dorman EK, Cutts F et al. (1999) Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 353, 632-636.
23. Tarimo DS, Minjas JN & Bygbjerg IC (2002) Sulfadoxine-pyrimetharmine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy. Tropical Medicine and International Health 7, 592-598.
24. White NJ (1999) Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41, 301-308.
25. WHO (1996) Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria in Areas with Intense Transmission. World Health Organization, Geneva.
26. WHO Expert Committee on Malaria (2000) World Health Organization Technical Report Series, Vol. 892, WHO, Geneva, 1-74.